23rd Mar 2016 10:24
LONDON (Alliance News) - Akers Biosciences Inc on Wednesday said it has secured a US patent covering its methods for detecting heparin factor 4 antibodies.
Akers said the US Patent & Trademark Office has allowed a patent covering the firm's PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 tests.
The tests are designed to quickly determine if a patient is being treated with heparin, the blood thinner, and could be developing heparin-induced thrombocytopenia, which turns the heparin into a clotting agent.
Akers shares were down 10% to 110.00 pence Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
AKR.L